Gene therapy and coronary artery bypass grafting: Current perspectives

Current Opinion in Molecular Therapeutics

Volumn 8, Issue 4, 2006, Pages 288-294

  George, Sarah J ^a   Channon, Keith M ^b   Baker, Andrew H ^c  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Adenoviruses; Bypass grafts; Gene therapy; Smooth muscle cells; Veins

Indexed keywords

ACETYLSALICYLIC ACID; ADENOVIRUS VECTOR; ANTIINFLAMMATORY AGENT; CLOPIDOGREL; COLESTYRAMINE; EDIFOLIGIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LENTIVIRUS VECTOR; MEVINOLIN; OLIGONUCLEOTIDE; PARVOVIRUS VECTOR; PLACEBO; PROTEIN 35K; PROTEIN P53; SUPEROXIDE DISMUTASE; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE PLASMINOGEN ACTIVATOR; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C; VIRUS ENVELOPE PROTEIN; VIRUS ENVELOPE PROTEIN G;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG SAFETY; DRUG TARGETING; GENE OVEREXPRESSION; GENE THERAPY; GRAFT FAILURE; GRAFT OCCLUSION; GRAFT PATENCY; HUMAN; INFLAMMATION; INTERMETHOD COMPARISON; MUTAGENESIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OXIDATIVE STRESS; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PROTEIN DEGRADATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SAPHENOUS VEIN GRAFT; SEROTYPE; THROMBOSIS; VASCULAR SMOOTH MUSCLE; VIRAL GENE DELIVERY SYSTEM;

CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY BYPASS; CORONARY THROMBOSIS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRAFT OCCLUSION, VASCULAR; HUMANS; SAPHENOUS VEIN; VASCULAR PATENCY;

EID: 33747492001     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Buxton BF, Fuller J: Clinical trials and graft patency data in coronary artery surgery - a 30-year perspective. Heart Lung Circ (2004) 13(Suppl 3):S7-S12.
2. Okrainec K, Platt R, Pilote L, Eisenberg MJ: Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: A review of randomized controlled trials. JAMA (2005) 45(2):177-184.
3. Ehsan A, Mann MJ, Dell'Acqua G, Dzau VJ: Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thor Card Surg (2001) 121(4):714-722.
4. Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS, Cooke J, Kaneda Y, Dzau VJ: Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci USA (1995) 92(10):4502-4506.
5. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, Namini H, Hamdan AD, Roddy SP, Belkin M, Berceli SA, DeMasi RJ, Samson RH, Berman SS, PREVENT III Investigators: Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg (2006) 43(4):742-751
6. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB, Lorenz TJ, Goyal A, Gibson M, Mac MJ, Gennevois D, Califf RM, Kouchoukos NT, PREVENT IV Investigators: Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery. PREVENT IV: A randomized controlled trial. JAMA (2005) 294(19):2446-2454.
7. Cohen CJ, Shieh JT, Pickles RJ, Okegawa T, Hsieh JT, Bergelson JM: The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci USA (2001) 98(26):15191-15196.
8. Newman KD, Dunn PF, Owens JW, Schulick AH, Virmani R, Sukhova G, Libby P, Dichek DA. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest (1995) 98(26):2955-2965.
9. Channon KM, Qian H, Youngblood SA, Olmez E, Shelly GA, Neplioueva V, Blazing MA, George SE. Acute host-mediated endothelial injury after adenoviral gene transfer in normal rabbit arteries. Circ Res (1998) 82(12):1253-1262.
10. Havenga MJ, Lemckert AA, Grimbergen JM, Vogels R, Huisman LG, Valerio D, Bout A, Quax PH: Improved adenovirus vectors for infection of cardiovascular tissues. J. Virol (2001) 75(11):3335-3342.
11. Gaggar A, Shayakhmetov DM, Liszewski MK, Atkinson JP, Lieber A: Localization of regions in CD46 that interact with adenovirus. Virology (2005) 79(12):7503-7513.
12. Gaggar A, Shayakhmetov DM, Lieber A: CD46 is a cellular receptor for group B adenoviruses. Nat Med (2003) 9(11):1408-1412.
13. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousava N, Curiel DT: An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol (1998) 72(12):9706-9713.
14. Work LM, Reynolds PN, Baker AH: Improved gene delivery to human saphenous vein cells and tissue using a peptide-modified adenoviral vector. Gen Vacc Therapy (2004) 2(1):14.
15. Work LM, Nicklin SA, Brain NJ, Dishart KL, Von Seggem DJ, Hallek M, Buning H, Baker AH: Development of efficient viral vectors selective for vascular smooth muscle cells. Mol Ther (2004) 9(2):198-208.
16. Akowuah EF, Gray C, Lawrie CG, Sheridan PJ, Su CH, Bellinger T, Brisken AF, Gunn J, Crossman DC, Francis SE, Baker AH, Newman CM: Ultrasound-mediated delivery of TIMP-3 plasmid DNA into saphenous vein leads to increased lumen size in a porcine interposition graft model. Gene Therapy (2005) 12(14):1154-1157.
17. Parkes R, Meng QH, Siapati KE, McEwan JR, Hart SL: High efficiency transfection of porcine vascular cells in vitro with a synthetic vector system. J Gen Med (2002) 4(3):292-299.
18. Nicklin SA, Buening H, Dishart KL, de Alwis M, Girod A, Hacker U, Thrasher AJ, Ali RR, Hallek M, Baker AH: Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther (2001) 4(3):174-181.
19. Pajusola K, Gruchala M, Joch H, Luscher TF, Ylä-Herttuala S, Bueler H: Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells. J Virology (2002) 76(22):11530-11540.
20. Denby L, Nicklin SA, Baker AH: Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation. Gene Ther (2005) 12(20):1534-1538.
21. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R Zhou XL, Wilson JM: Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol (2004) 78(12):6381-6388.
22. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wison JM: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA (2002) 99(18): 11854-11859.
23. Gregorevic P, Blankinship MJ, Allen JM, Crawford RVV, Meuse L, Miller DG, Russell DW, Chamberlain JS: Systemic delivery of germs to striated muscles using adeno-associated viral vectors. Nat Med (2004) 10(8):828-834.
24. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, Chen C, Li J, Xiao X: Adeno-associated virus serotype 8 efficiently delivers germs to muscle and heart. Nat Biotech (2005) 23(3):321-328.
25. Zabner J, Seiler M, Walters R, Kotin RM, Fulgeras W, Davidson BL, Chiorini JA: Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol (2000) 74(8):3852-3858.
26. Seiler M, Miller D, Zabner J, Halbert C: Adeno-associated virus types 5 and 6 use distinct receptors for cell entry. Hum Gene Ther (2006) 17(1):10-19.
27. Work LM, Buning H, Hunt E, Nicklin SA, Denby L, Britton N, Leike K, Odenthal M, Drebber U, Hallek M, Baker AH: Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol Ther (2006) 13(4):683-693.
28. Dishart KL, Denby L, George SJ, Nicklin SA, Yendluri S, Tuerk MJ, Kelley MP, Donahue BA, Newby AC, Harding TC, Baker AH: Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: Implications for gene therapy. J Mol Cell Cardiol (2003) 35(7):739-748.
29. Qian Z, Haessler M, Lemos JA, Arsenault JR, Aguirre JE, Gilbert JR, Bowler RP, Park F: Targeting vascular injury using Hantavirus-pseudotyped lentiviral vectors. Mol Ther (2006) 13(4):694-704.
30. Yanez-Munoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ, Buch P, MacLaren RE, Anderson PN, Barker SE, Duran Y, Bartholomae C, von Kalle C, Heckenlively JR, Kinnon C, Ali RR, Thrasher AJ: Effective gene therapy with nonintegrating lentiviral vectors. Nat Med (2006) 12(3):348-353.
31. Motwani JG, Topol EJ: Aortocoronary saphenous vein graft disease: Pathogenesis, predisposition, and prevention. Circulation (1998) 97(9):916-931.
32. Bryan AJ, Angelini GD: The biology of saphenous vein graft occlusion: Etiology and strategies for prevention. Curr Opin Cardiol (1994) 9(6):641-649.
33. West NE, Qian H, Guzik TJ, Black E, Cai S, George SE, Channon KM: Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling: Effects on vascular smooth muscle cell differentiation and superoxide production. Circulation (2001) 104(13):1526-1532.
34. Shi Y, Patel S, Davenpeck KL, Niculescu R, Rodriguez E, Magno MG, Ormont ML, Mannion JD, Zalewski A: Oxidative stress and lipid retention in vascular grafts: Comparison between venous and arterial conduits. Circulation (2001) 103(19):2408-2413.
35. Waugh JM, Yuksel E, Li JJ, Kuo MD, Kattash M, Saxena R, Geske R, Thung SN, Shenaq SM, Woo SL: Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ Res (1999) 84(1):84-92.
36. Zoldhelyi P, McNatt J, Shelat HS, Yamamoto Y, Chen ZQ, Willerson JT: Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation (2000) 101(3):289-295.
37. Nishida T, Ueno H, Atsuchi N, Kawano R, Asada Y, Nakahara Y, Kamikubo Y, Takeshita A, Yasui H: Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced redurrent thrombosis in the injured carotid artery of the rabbit. Circ Res (1999) 84(12):1446-1452.
38. Gangadharan SP, Imai M, Rhynhart KK, Sevigny J, Robson SC, Conte MS: Targeting platelet aggregation: CD39 gone transfer augments nucleoside triphosphate diphosphohydrolase activity in injured rabbit arteries. Surgery (2001) 130(2):296-303.
39. Waugh JM, Kattash M, Li J, Yuksel E, Kuo MD, Lussier M, Weinfeld AB, Saxena R, Rabinovsky ED, Thung S, Woo SL, Shenaq SM: Gene therapy to promote thromboresistance: Local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc Natl Acad Sci USA (1999) 96(3):1065-1070.
40. Tabuchi N, Shichiri M, Shibamiya A, Koyama T, Nakazawa F, Chung J, Hirosawa S, Sunamori M: Non-viral thrombomodulin gene transfer prevents early loss of thromboresistance of grafted veins. Eur J Cardio-Thoracic Surg (2004) 26(5):995-1001.
41. Petrofski JA, Hata J, Williams ML, Parsa CJ, Thompson RB, Hanish SI, Gehrig TR, Koch WJ, Milano CA: A Gbetagamma inhibitor reduces intimal hyperplasia in aortocoronary saphenous vein grafts. J Thorac Cardiovasc Surg (2005) 130(6):1683-1690.
42. George S, Johnson J, Angelini G, Newby A, Baker A: Adenovirus-mediated gene transfer of the human TIMP-1 gene Inhibits smooth muscle cell migration and neomintimal formation in human saphenous vein. Hum Gene Ther (1998) 9(6):867-877.
43. George SJ, Lloyd CT, Angelini GD, Newby AC, Baker AH: Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation (2000) 101(3):296-304.
44. George SJ, Baker AH, Angelini GD, Newby AC: Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther (1998) 5(11):1552-1560.
45. Wolff RA, Ryomoto M, Stark VE, Malinowski R, Tomas JJ, Stinauer MA, Hullett DA, Hoch JR: Antisense to transforming growth factor-β1 messenger RNA reduces vein graft intimal hyperplasis and moncyte chemotactic protein 1. J Vasc Surg (2005) 41(3):498-508.
46. Matsumoto T, Komori K, Yonemitsu Y, Morishita R, Sueishi K, Kaneda Y, Sugimachi K: Hermagglutinating virus of Japan-liposome-mdiated gene transfer of endothelial cell nitric oxide synthase inhibits intimal hyperplasia of canine grafts under conditions of poor runoff. J Vasc Surg (1998) 27(1):135-144.
47. Kibbe MR, Tzeng E, Gleixner S, Watkins S, Kovesdi L, Lizonova A, Makaroun MS, Billiar T, Rhee R: Adenovirus-meidated gene transfer of human inducible nitric oxide synthase in porcine vein graft inhibits intimal hyperplasia. J Vasc Surg (2001) 34(1):156-165.
48. Puhakka HL, Turunen P, Gruchala M, Bursill C, Heikura T, Vajanto I, Greaves DR, Channon K, Ylä-Herttuala S: Effects of vaccinia virus anti-inflammatory protein 35K and TIMP-1 gene transfers on vein graft stenosis in rabbits. In Vivo (2005) 19(3):515-521.
49. Ali Z, Alp N, Tatham A, Greaves D, Channon K: Gene transfer of a broad specturm CC-chemokine inhibitor reduces vein graft atherosclerosis in apolipoprotein E-knockout mice. Circulation (2005) 112(9 Suppl):I235-241.
50. Wan S, George SJ, Nicklin SA, Yim AP, Baker AH: Overexpression of p53 increases lumen size and blocks neointima formation in porcine interposition vein grafts. Mol Ther (2004) 9(5):689-698.
51. Puhakka HL, Turunen P, Juha R, Hiltunen MO, Turunen MP, Ylä-Herttuala S: Tissue inhibitor of metalloproteinase 1 adenoviral gene therapy alone is equally effective in reducing restenosis as combination gene therapy in a rabbit restenosis model. J Vasc Res (2005) 42(5):361-367.
52. Turunen P, Puhakka HL, Keikura T, Romppanen E, Inkala M, Leppanen O, Ylä-Herttuala S: Extracellular superoxide dismutase with vaccinia virus anti-inflammatory protein 35K or tissue inhibitor of metalloproteinase-1: Combination gene therapy in the treatment of vein graft stenosis in rabbits. Hum Gene Ther (2006) 17(4):405-414.